8-K: Alkermes Reports Strong Q3 2024 Results Driven by Proprietary Product Growth

Alkermes announced a solid third quarter in 2024, with a notable 18% year-over-year increase in net sales of proprietary products and GAAP net income from continuing operations of $92.8 million.

Summary

• Alkermes reported its financial results for the third quarter of 2024, showing a total revenue of $378.1 million.
• The company's proprietary product net sales increased by approximately 18% year-over-year, reaching $273.0 million.
• GAAP net income from continuing operations was $92.8 million, resulting in diluted GAAP earnings per share of $0.56.
• LYBALVI revenues grew significantly, with a 47% increase in revenue and a 37% increase in total prescriptions compared to the third quarter of 2023.
• VIVITROL revenues also saw growth, increasing by 14% compared to the same period last year, driven by the alcohol dependence indication.
• The company repurchased approximately 4.4 million ordinary shares for a total of $115.6 million during the quarter.
• Alkermes reiterated its financial expectations for 2024, initially set in February 2024.
• The company is advancing its orexin 2 receptor agonist, ALKS 2680, with ongoing phase 2 studies in narcolepsy and plans to initiate a phase 2 study in idiopathic hypersomnia in 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth in key products and reiteration of financial guidance. However, there are some negative aspects such as a slight decrease in total revenue and a decrease in non-GAAP net income, which temper the overall sentiment.

Positives

• Alkermes experienced strong growth in its proprietary product portfolio, with an 18% increase in net sales year-over-year.
• LYBALVI showed impressive growth, with a 47% increase in revenue and a 37% increase in prescriptions compared to the third quarter of 2023.
• VIVITROL also demonstrated solid growth, with a 14% increase in revenue driven by the alcohol dependence indication.
• The company achieved a GAAP net income from continuing operations of $92.8 million.
• Alkermes is actively investing in its pipeline, particularly ALKS 2680, which has the potential to transform the treatment of hypersomnolence disorders.
• The company has a strong cash position with $927.8 million in cash, cash equivalents, and total investments.
• The share repurchase program demonstrates confidence in the company's value.

Negatives

• Total revenues slightly decreased to $378.1 million from $380.9 million in the same quarter of the previous year.
• Manufacturing and royalty revenues decreased to $105.1 million from $149.1 million in the third quarter of 2023, partly due to the expiration of a royalty on U.S. net sales of INVEGA SUSTENNA in August 2024.
• Non-GAAP net income from continuing operations decreased to $121.4 million from $150.4 million in the third quarter of 2023.
• The company's cash, cash equivalents, and total investments decreased from $962.5 million at June 30, 2024, to $927.8 million at September 30, 2024.

Risks

• The company faces risks related to the success of its clinical development activities, including the potential for delays or negative results.
• Regulatory authorities may make adverse decisions regarding the company's products.
• There is a risk that the company and its licensees may not be able to continue to successfully commercialize their products.
• The company could face reductions in payment rates or reimbursement for its products.
• The company's products may prove difficult to manufacture or be precluded from commercialization due to third-party proprietary rights.
• The company is subject to risks related to litigation, including patent litigation, which could lead to competition from generic drug manufacturers.

Future Outlook

Alkermes expects to complete phase 2 studies for ALKS 2680 in narcolepsy in 2025 and prepare for potential registrational studies. The company also plans to initiate a phase 2 study in patients with idiopathic hypersomnia in 2025. Alkermes reiterated its 2024 financial expectations, including total revenues between $1.5 billion and $1.6 billion, and EBITDA between $445 million and $485 million.

Management Comments

• Richard Pops, Chief Executive Officer of Alkermes, stated that the third quarter financial results reflect strong year-over-year growth of the company's portfolio of proprietary commercial products.
• He also mentioned that growing proprietary commercial products and advancing the pipeline, particularly ALKS 2680, will be key drivers of shareholder value.
• Mr. Pops noted that 2025 has the potential to be a transformational year for Alkermes as they expect to complete phase 2 studies for ALKS 2680 and prepare for potential registrational studies.

Industry Context

Alkermes' focus on neuroscience and the development of novel treatments for neurological disorders aligns with the growing demand for innovative therapies in this space. The company's progress with ALKS 2680, an orexin 2 receptor agonist, positions it in a potentially significant new therapeutic category. The company's performance is being closely watched by investors and competitors in the biopharmaceutical industry.

Comparison to Industry Standards

• Alkermes' 18% year-over-year growth in proprietary product sales is a strong performance compared to many established pharmaceutical companies, although direct comparisons are difficult without specific competitor data.
• The 47% growth in LYBALVI revenue is particularly impressive, indicating strong market adoption and potential for future growth, which is above average for new product launches in the pharmaceutical industry.
• The company's focus on orexin 2 receptor agonists is a novel approach, and its progress with ALKS 2680 is being closely watched by competitors such as Jazz Pharmaceuticals, who have a competing product in the narcolepsy space.
• Alkermes' financial performance is in line with expectations for a company of its size and stage of development, with a focus on profitability and cash flow management.
• The company's share repurchase program is a common practice among publicly traded companies, indicating confidence in the company's value and future prospects.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and share repurchase program.
• Employees will be impacted by the company's continued growth and investment in research and development.
• Customers will benefit from the company's innovative treatments for neurological disorders.
• Suppliers and creditors will be impacted by the company's financial stability and growth.

Next Steps

• Alkermes will continue to advance its phase 2 studies for ALKS 2680 in narcolepsy.
• The company plans to initiate a phase 2 study in patients with idiopathic hypersomnia in 2025.
• Alkermes will continue to manage the business to deliver significant profitability and cash flow while investing in strategic initiatives.
• The company will continue to execute its share repurchase program.

Key Dates

Keywords

Alkermes, Financial Results, Proprietary Products, LYBALVI, VIVITROL, ARISTADA, Orexin 2 Receptor Agonist, ALKS 2680, Narcolepsy, Idiopathic Hypersomnia, Share Repurchase, Pharmaceuticals, Neuroscience